AHEAD - A3 A45
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer’s Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer’s Disease and Intermediate Amyloid (A3 Trial)
- Sex at Birth: Any
- Age: Adult (18 - 64), Older Adult (65+)
- Accepting Healthy People: Yes
- Type: Prevention
- Trial Phase: Phase III
- Conditions Being Studied: Brain and Nervous System, Healthy Volunteers
Study Purpose
The purpose of this study is to test whether an investigational drug, BAN2401 (lecanemab) can help reduce the risk of developing AD dementia. This study if for healthy volunteers without a diagnosis of dementia or Alzheimer's.
Who Can Participate
Age: 55-80 years old
Locations
UH Foley ElderHealth Center
3619 Park East Drive
Beachwood OH, 44122
UH Cleveland Medical Center
11100 Euclid Avenue
Cleveland OH, 44106
- UH IRB: SITE00001237
- StudyID: 2020-0178
- ClinicalTrials.gov: NCT04468659
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422